-
-
-
-
-
-
-
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
-
-
-
-
-
-
-
Virax Biolabs closes $5 million private placement
-
-
-
-
-
-
-
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
-
-
-
-
-
-
-
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
-
-
-
-
-
-
-
Virax Biolabs' (VRAX) CEO Issues Letter to Shareholders
-
-
-
-
-
-
-
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
-
-
-
-
-
-
-
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
-
1,210,210 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

